0001493152-26-024786.txt : 20260521 0001493152-26-024786.hdr.sgml : 20260521 20260521144429 ACCESSION NUMBER: 0001493152-26-024786 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260521 DATE AS OF CHANGE: 20260521 EFFECTIVENESS DATE: 20260521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lantern Pharma Inc. CENTRAL INDEX KEY: 0001763950 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 463973463 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-584796 FILM NUMBER: 261007855 BUSINESS ADDRESS: STREET 1: 1920 MCKINNEY AVENUE STREET 2: 7TH FLOOR CITY: DALLAS STATE: TX ZIP: 75201 BUSINESS PHONE: 972-277-1136 MAIL ADDRESS: STREET 1: 1920 MCKINNEY AVENUE STREET 2: 7TH FLOOR CITY: DALLAS STATE: TX ZIP: 75201 FORMER COMPANY: FORMER CONFORMED NAME: Lantern Pharma DATE OF NAME CHANGE: 20190108 D 1 primary_doc.xml X0708 D LIVE 0001763950 Lantern Pharma Inc. 1920 MCKINNEY AVENUE, 7TH FLOOR DALLAS TX TEXAS 75201 (972) 277-1136 TEXAS None Lantern Pharma Corporation true Panna Sharma 1920 McKinney Avenue, 7th Floor Dallas TX TEXAS 75201 Executive Officer Director Chief Executive Officer, President Donald Jeffrey Keyser 1920 McKinney Avenue, 7th Floor Dallas TX TEXAS 75201 Director Chairman of the Board David R. Margrave 1920 McKinney Avenue, 7th Floor Dallas TX TEXAS 75201 Executive Officer Chief Financial Officer, Secretary Kishor G. Bhatia 1920 McKinney Avenue, 7th Floor Dallas TX TEXAS 75201 Executive Officer Chief Scientific Officer Vijay Chandru 1920 McKinney Avenue, 7th Floor Dallas TX TEXAS 75201 Director Maria Maccecchini 1920 McKinney Avenue, 7th Floor Dallas TX TEXAS 75201 Director Lee T. Schalop 1920 McKinney Avenue, 7th Floor Dallas TX TEXAS 75201 Director David S. Silberstein 1920 McKinney Avenue, 7th Floor Dallas TX TEXAS 75201 Director Pharmaceuticals Decline to Disclose 06b false 2026-05-14 false true true true private placement of common stock purchase warrants;claiming additional Section 4(a)(2) exemption false 0 0 0 0 The investors paid nothing for the warrants. The warrants were issued as additional consideration for shares of common stock purchased in a concurrent registered offering. false 6 0 0 0 false Lantern Pharma Inc. /s/ David R. Margrave David R. Margrave Chief Financial Officer 2026-05-21